Sign In
Buy CORT
$72.65
+1.45 (+2.04%)
At Close: Jun 03, 2026
Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results
04:10pm, Thursday, 06'th May 2021
MENLO PARK, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe meta
Corcept Therapeutics (CORT) Sees Hammer Chart Pattern: Time to Buy?
07:09am, Wednesday, 05'th May 2021
Corcept Therapeutics (CORT) has been struggling lately, but the selling pressure may be coming to an end soon
Earnings Preview: Corcept Therapeutics (CORT) Q1 Earnings Expected to Decline
01:46pm, Monday, 26'th Apr 2021
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Corcept (CORT) Down 11.1% Since Last Earnings Report?
12:07pm, Thursday, 25'th Mar 2021
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept (CORT) Begins Adrenal Cancer Study on Relacorilant
10:37am, Tuesday, 16'th Mar 2021
Corcept (CORT) commences phase Ib study on relacorilant in combination with Keytruda for treating patients with adrenal cancer with cortisol excess.
MENLO PARK, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe me
Corcept (CORT) Q4 Earnings In Line, Revenues Miss Estimates
11:23am, Wednesday, 24'th Feb 2021
Corcept's (CORT) earnings meet estimates in the fourth quarter of 2020 while revenues miss the same.
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
04:05pm, Tuesday, 23'rd Feb 2021
MENLO PARK, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe met
AMRX or CORT: Which Is the Better Value Stock Right Now?
12:27pm, Wednesday, 10'th Feb 2021
AMRX vs. CORT: Which Stock Is the Better Value Option?
Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today
12:02pm, Tuesday, 09'th Feb 2021
Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeuti
Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View
10:37am, Tuesday, 09'th Feb 2021
Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021.
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript
10:56pm, Monday, 08'th Feb 2021
Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript
Financial Highlights, 2021 Revenue Guidance and Legal Update
Why Corcept Therapeutics (CORT) Might Surprise This Earnings Season
09:50am, Friday, 05'th Feb 2021
Corcept Therapeutics (CORT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Corcept Therapeutics to Announce Preliminary Selected Financial Results, Provide Corporate Update and Host Conference Call
04:05pm, Monday, 01'st Feb 2021
MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial result
